Heico stock has lagged, a very rare thing. That was the opportunity. Here's a quick summary of the wow quarter and the guidance. The business is on solid footing and the stock is wildly under-owned. There's alot more to like than just crowded AI stocks. HEI is one. This is NOT financial advice, this is for educational and informational purposes only. Please do your own research.

The powerful forward story is the pipeline built to answer the only real bear concern—concentration. The first answer is Foundayo, the newly approved oral GLP-1 pill, the only one dosable anytime without food or water. A pill is a step-change in scalability: no cold chain, no injection, far cheaper to manufacture, and the key to unlocking hundreds of millions of patients globally and in primary care—early uptake shows ~80% of scripts going to new-to-class patients. The second is retatrutide, a triple hormone agonist that delivered ~28% weight loss over 18 months in Phase 3, approaching surgical outcomes. Behind them sits a 42-program Phase 3 engine, spanning expanding indications (sleep apnea, heart failure, MASH-a dangerous form of fatty liver disease where fat builds up in the liver and eventually causes inflammation and liver damage.) And then theres, Alzheimer’s, oncology, and immunology. There's So much in Lilly's pipeline to like.

What makes Shopify special begins with a cultural transformation that is widely underappreciated. After its 2022 reset, Shopify sold its capital-intensive logistics arm, narrowed focus to its core platform, and embraced radical operating discipline—CEO Tobi Lütke’s mandate that teams prove a job cannot be done with AI before requesting new headcount. The result is three consecutive years of flat-to-declining headcount while revenue grew ~30%+ annually, with operating expenses falling to 37% of revenue. This is a company spending less on people while shipping faster, and it is the engine behind the swing from cash-burning growth to ~$2 billion of annual free cash flow and a new $2 billion buyback.